Merz Aesthetics' Ultherapy PRIME Now FDA-Approved for Knees Treatments

The non-surgical body treatment market is witnessing a significant shift, with an increasing demand for treatments beyond the face and neck. One area that has gained significant attention in recent times is the knees, with the trend of "Hollywood knees" fueling the desire for non-invasive treatments.

Merz Aesthetics, a leading medical aesthetics business, has announced that the U.S. Food and Drug Administration (FDA) has cleared Ultherapy PRIME to improve the appearance of skin laxity on the knees. This milestone marks a significant expansion of Ultherapy PRIME's growing portfolio of cleared body indications.

Ultherapy PRIME is a non-surgical body treatment developed by Merz Aesthetics, which uses advanced microfocused ultrasound with vivid real-time visualization (MFU-V) to stimulate the body's natural collagen and elastin production. The device is designed to deliver a non-surgical lift with natural-looking, long-lasting results for the face and body.

The clearance of Ultherapy PRIME for knees treatments is a significant development in the field of medical aesthetics. According to Patrick Urban, President of Merz Aesthetics North America, "Being the first to bring FDA-cleared real-time visualization to the knees represents a meaningful milestone. However, this launch is about more than a new indication; it's about expanding the addressable market for non-invasive lifting and firming."

Ultherapy PRIME treats multiple skin depths, allowing practitioners to tailor treatment to each patient's unique anatomy. The device typically requires a single session with no downtime and is safe for all skin tones.

The clearance of Ultherapy PRIME for knees treatments is a testament to the company's commitment to advancing science-backed innovation and expanding non-invasive treatment possibilities for healthcare professionals and their patients. As Dr. Samantha Kerr, Chief Scientific Officer at Merz Aesthetics, noted, "The new knees indication marks another monumental moment for Ultherapy PRIME. It underscores our commitment to advancing science-backed innovation and expanding non-invasive treatment possibilities for healthcare professionals and their patients."

Ultherapy PRIME builds on the proven legacy of Ultherapy, recognized as the Gold Standard in non-invasive skin lifting, with more than 4 million treatments performed globally and 95% patient satisfaction at year one. As Dr. Jennifer Levine, double board-certified facial plastic surgeon in New York City, noted, "The advancement of Ultherapy PRIME for the knees represents an important advancement and personalized approach to addressing these concerns and growing patient demand."

As Ultherapy PRIME continues to redefine the future of nonsurgical skin lifting, Merz Aesthetics will transition away from the legacy Ultherapy device, with full service and support concluding on September 30, 2027. Merz Aesthetics is committed to ensuring a smooth transition and will provide guidance and resources throughout the process.

## Ultherapy PRIME Specifications

| Feature | Description | | --- | --- | | Treatment Area | Knees | | Treatment Type | Non-surgical body treatment | | Device Type | Advanced microfocused ultrasound with vivid real-time visualization (MFU-V) | | Skin Depths | Multiple skin depths | | Treatment Sessions | Single session | | Downtime | No downtime | | Skin Tones | Safe for all skin tones |

## Conclusion

The clearance of Ultherapy PRIME for knees treatments is a significant development in the field of medical aesthetics. With its advanced technology and non-invasive approach, Ultherapy PRIME is poised to revolutionize the way healthcare professionals and their patients address skin laxity on the knees. As the market continues to evolve, it will be exciting to see how Ultherapy PRIME shapes the future of nonsurgical skin lifting.